Publication Name	World Journal of Gastroenterology
Manuscript ID	25665
Country	Italy

Received	2016-03-18 08:38
Peer-Review Started	2016-03-21 16:41
To Make the First Decision	2016-04-14 11:14
Return for Revision	2016-04-17 17:36
Revised
Second Decision	2016-08-01 19:24
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-08-08 17:32
Articles in Press	2016-08-08 17:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-08-26 09:56
Publish the Manuscript Online	2016-09-08 10:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Challenges of advanced hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Stefano Colagrande, Andrea L Inghilesi, Sami Aburas, Gian G Taliani, Cosimo Nardi and Fabio Marra
Funding Agency and Grant Number
Corresponding Author	Stefano Colagrande, MD, Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, Largo Brambilla 3, I-50134 Florence, Italy. stefano.colagrande@unifi.it
Key Words	Barcelona Clinic Liver Cancer; Portal vein thrombosis; Modified Response Evaluation Criteria in Solid Tumors; Advanced hepatocellular carcinoma management; Advanced hepatocellular carcinoma second line therapies; Sorafenib
Core Tip	Hepatocellular carcinoma (HCC) is an aggressive malignancy, which accounts for great part of all cancer deaths each year. Its management is complex, and although the surveillance performed, many patients have an advanced stage. This comprehends an heterogeneous groups with different clinical condition; sorafenib is the only approved treatment, however affected by many adverse events. No single agent or combination therapies have been shown to impact outcomes after sorafenib failure. Loco-regional therapies as TAE/TACE and TARE have also been tested and at now are under evaluation. This review will focus on patients with advanced HCC and highlights potential and limit of the therapies.
Publish Date	2016-09-08 10:53
Citation	Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659
URL	http://www.wjgnet.com/1007-9327/full/v22/i34/7645.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i34.7645

Full Article (PDF)	WJG-22-7645.pdf
Full Article (Word)	WJG-22-7645.doc
Manuscript File	25665-Review.docx
Answering Reviewers	25665-Answering reviewers.pdf
Audio Core Tip	25665-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	25665-Conflict-of-interest statement.pdf
Copyright License Agreement	25665-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25665-Language certificate.pdf
Peer-review Report	25665-Peer-review(s).pdf
Scientific Misconduct Check	25665-Scientific misconduct check.pdf
Scientific Editor Work List	25665-Scientific editor work list.pdf